Jinal Sharma

Jinal Sharma is an associate in Nutter’s Corporate Department. She focuses her practice on advising clients on all aspects of corporate and securities law, including mergers and acquisitions (public and private), public and private company securities law matters, venture capital and angel financings, and general corporate governance, with a particular focus on the technology and life sciences industries.

Notable Experience and Client Impact

• Advised Aerovate Therapeutics (Nasdaq: AVTE), a biotechnology company focused on improving the lives of patients with rare cardiopulmonary disease, on its merger with Jade Biosciences in an all-stock transaction
• Advised Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates, in its $2.4 billion sale to AstraZeneca
• Represented VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for immune-inflammatory diseases, in its merger with Notable Labs, Inc.
• Advised ElevateBio, LLC, a technology-driven company built to power the development of transformative cell and gene therapies, on it $401 million Series D financing
• Represented Concert Pharmaceuticals (NASDAQ: CNCE), a biotechnology company pioneering the use of deuterium in medicinal chemistry, in its merger with Sun Pharmaceutical
• Advised Talaris Therapeutics, Inc. (NASDAQ: TALS), a cell therapy company developing an innovative method of allogeneic hematopoietic stem cell transplantation, in its merger with Tourmaline Bio, Inc.

Read More

Education

Northeastern University School of Law, J.D.
American University, B.A.

Admissions

• Massachusetts

Languages

• Hindi